Castration resistant describes a prostate cancer that continues to grow even after testosterone has been reduced to very low levels. Normally, prostate cancer cells need testosterone to fuel their growth, so one of the first treatments is to cut off that supply, either through surgery or medication. When the cancer finds ways to keep growing despite testosterone levels dropping below 50 ng/dL (the threshold that defines a “castrate” environment), it is reclassified as castration-resistant prostate cancer, or CRPC.
Why Lowering Testosterone Works at First
Most prostate cancers are initially hormone-sensitive. Their cells rely on testosterone binding to a protein called the androgen receptor, which then switches on genes that tell the cell to grow and divide. Androgen deprivation therapy, often called ADT, works by dramatically lowering testosterone through medication or surgical removal of the testes. For many men, this causes the cancer to shrink or stabilize, sometimes for years.
But prostate cancer cells are under intense pressure to survive, and over time they develop workarounds. The transition from hormone-sensitive to castration-resistant is not a sudden event. It’s a gradual adaptation, and the first sign is typically a rising PSA (prostate-specific antigen) level on blood tests even while testosterone remains at castrate levels.
How Cancer Cells Bypass Low Testosterone
The cancer doesn’t stop caring about the androgen receptor. Instead, it finds new ways to activate it. Several mechanisms drive this shift, and a single tumor may use more than one at the same time.
One common trick is overproduction of the androgen receptor itself. Some cancer cells make extra copies of the receptor gene, which makes them extraordinarily sensitive to even trace amounts of testosterone still circulating in the body. Think of it like turning the volume knob way up so you can hear a whisper.
Another mechanism involves mutations in the receptor that allow it to respond to a wider range of hormones, not just testosterone. Some mutated receptors can even be activated by the very drugs designed to block them.
Perhaps the most studied adaptation is the production of a shortened version of the androgen receptor known as AR-V7. This truncated receptor is missing the part where testosterone would normally need to attach. Without that requirement, it stays permanently switched on, driving cancer growth with no hormone signal at all. When AR-V7 is detected in a patient’s circulating tumor cells, it predicts that certain newer hormone-blocking therapies are unlikely to work.
Cancer cells can also manufacture their own androgens internally. Even when blood testosterone is nearly undetectable, tumor tissue can contain measurable levels of active hormones. The cells achieve this through multiple biochemical routes: converting cholesterol into androgens directly, hijacking hormone precursors produced by the adrenal glands, and using alternative enzymatic pathways that produce potent androgens while bypassing testosterone entirely. This internal production creates a self-sustaining fuel supply that external hormone therapy can’t fully shut down.
Non-Metastatic vs. Metastatic CRPC
Once prostate cancer becomes castration resistant, it falls into one of two categories based on whether it has spread. Non-metastatic CRPC (nmCRPC) means the cancer is growing, shown by a rising PSA, but conventional imaging like CT scans and bone scans don’t detect spread to other parts of the body. Metastatic CRPC (mCRPC) means spread has been confirmed, most commonly to bones or lymph nodes.
That distinction is becoming blurrier with newer imaging technology. PSMA PET scans, which detect a protein on the surface of prostate cancer cells, are far more sensitive than traditional scans. In one large study of 200 men classified as non-metastatic by conventional imaging, PSMA PET found positive results in 98% of them, with 55% actually having distant spread to bones or lymph nodes outside the pelvis. This means many men labeled as non-metastatic on standard scans may already have early metastatic disease.
How PSA Doubling Time Predicts Risk
For men with non-metastatic CRPC, how fast the PSA level is rising matters enormously. Doctors measure this as PSA doubling time, the number of months it takes for the PSA value to double. A doubling time of 10 months or less is considered high risk. In studies, the median time to developing metastases was just 9 months when PSA doubling time was under 3 months, compared to 50 months when it was 15 months or longer. Men with faster doubling times also had significantly worse metastasis-free survival: about 72% at four years versus 100% for those with slower PSA rises.
Treatment Options After Castration Resistance
Castration resistance doesn’t mean the cancer is untreatable. Several classes of therapy have been developed specifically for this stage.
Newer androgen receptor blockers work by more aggressively targeting the receptor or by cutting off the cancer’s ability to produce its own androgens. Some block the receptor from entering the cell nucleus where it does its work. One drug takes a different approach entirely, inhibiting the enzyme that produces androgens not only in the testes but also in the adrenal glands and within the tumor itself. These agents can extend survival and delay progression, though they tend to be less effective in tumors expressing the AR-V7 variant.
Chemotherapy with taxane-based drugs remains a backbone of treatment. The first of these was approved in 2004 as the first therapy to significantly improve survival in metastatic CRPC. A second-generation taxane, approved in 2010, provides an option for men whose cancer progresses after the first, adding a median of about 2.4 months of survival.
For men whose tumors carry specific DNA repair defects, a class of drugs called PARP inhibitors targets the cancer’s inability to fix damaged DNA. Four PARP inhibitors have been approved for certain prostate cancer cases, though they’re only effective in tumors with the right genetic profile.
Bone Health and Skeletal Complications
Because metastatic CRPC frequently spreads to bone, skeletal complications are a major concern. These include fractures through weakened bone, spinal cord compression, and the need for radiation or surgery to stabilize affected areas. Long-term testosterone suppression itself weakens bones, compounding the problem.
Bone-protective medications are routinely used alongside cancer treatment. These work by slowing the breakdown of bone tissue, reducing the risk of fractures and other skeletal events. They’re typically given as injections every few weeks for as long as the patient is at risk.
Survival and Outlook
Survival after a castration-resistant diagnosis varies widely depending on whether the cancer has spread, what treatments are used, and individual tumor biology. In a large retrospective analysis of over 11,000 men with metastatic CRPC, median overall survival was about 33 months from treatment. Men who received certain immunotherapy-based treatments had a median survival of 44 months, and 28% of those patients were still alive at five years.
These numbers represent meaningful improvement over the era before newer therapies were available. The landscape continues to shift as treatments are combined in new sequences and as genetic testing helps match patients to the therapies most likely to work for their specific tumor profile.